TH

Tyrosine 3-monooxygenase · P07101 · TH on Sugi Atlas →

240 patent compounds predicted against TH, 170 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
R-N-Propylnorapomorphine (SCHEMBL249729)	1.00	4/20
SCHEMBL1203698	1.00	4/20
SCHEMBL1203699	1.00	4/20
R-N-Propylnorapomorphine (SCHEMBL7997518)	1.00	4/20
SCHEMBL10754712	1.00	4/20
R-N-Propylnorapomorphine (SCHEMBL13398114)	1.00	4/20
R-N-Propylnorapomorphine (SCHEMBL13487203)	1.00	4/20
R-N-Propylnorapomorphine (SCHEMBL29447877)	1.00	4/20
Hydrochloric Acid (SCHEMBL10752801)	0.98	4/20
SCHEMBL15180898	0.87	4/20
SCHEMBL1345058	0.82	4/20
SCHEMBL1345853	0.82	4/20
SCHEMBL12877963	0.79	4/20
SCHEMBL29445852	0.78	4/20
SCHEMBL1345828	0.78	4/20
SCHEMBL1346853	0.78	4/20
SCHEMBL2556964	0.75	4/20
SCHEMBL12284669	0.75	4/20
SCHEMBL1347328	0.73	4/20
SCHEMBL1347330	0.73	4/20

Clinical trials — most relevant to TH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Adjunctive Role of Vitamin C on Pigment Recurrence (Randomized Clinical and Histological Trial)	PHASE4	UNKNOWN
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)	PHASE3	COMPLETED
Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)	PHASE2/PHASE3	UNKNOWN
Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease	PHASE1/PHASE2	COMPLETED
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease	PHASE2	COMPLETED
Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigmentation	PHASE2	ACTIVE_NOT_RECRUITING
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence	PHASE2	COMPLETED
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans	PHASE2	NOT_YET_RECRUITING
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)	PHASE2	ACTIVE_NOT_RECRUITING
Long-Term Study of Nitisinone to Treat Alkaptonuria	PHASE2	COMPLETED
The Effect of Antioxidants on Skin Blood Flow-BH4	PHASE1	COMPLETED
Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes	nan	COMPLETED
Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls	nan	SUSPENDED
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)	nan	WITHDRAWN
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder	nan	UNKNOWN
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	nan	COMPLETED
Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?	nan	UNKNOWN
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency	nan	UNKNOWN
Molecular Mechanisms of Mitral Regurgitation-Aim 2	nan	COMPLETED
The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation	nan	COMPLETED
Mechanisms of Action of Acetaminophen	nan	COMPLETED
Iron Status in Children With ADHD	nan	NOT_YET_RECRUITING
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD	nan	UNKNOWN
Estrogen Receptor 1 Gene Polymorphism Frequency in Fibromyalgia Syndrome	nan	COMPLETED
Vancomycin Associated Red Man Syndrome (RMS)	nan	COMPLETED
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation	nan	COMPLETED
Pharmacotoxicology of Trichloroethylene Metabolites	nan	COMPLETED
Prevention of Dichloroacetate Toxicity	nan	COMPLETED
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TH binder may also engage these)

Protein	Name	Similarity
P17289	—	1.000	P17289 →
P24529	—	0.999	P24529 →
P04177	—	0.998	P04177 →
Q76IQ3	—	0.995	Q76IQ3 →
A0A060X6Z0	—	0.993	A0A060X6Z0 →
P11982	—	0.992	P11982 →
A8X3V8	—	0.990	A8X3V8 →
Q0EAB8	—	0.989	Q0EAB8 →
P18459	—	0.989	P18459 →
O42091	—	0.988	O42091 →
Q525S7	—	0.987	Q525S7 →
P17276	—	0.987	P17276 →
Q7PZD5	—	0.987	Q7PZD5 →
E5KBU3	—	0.986	E5KBU3 →
A8HQD7	—	0.986	A8HQD7 →
Q2HZ26	—	0.986	Q2HZ26 →
P09810	—	0.986	P09810 →
TPH2	Tryptophan 5-hydroxylase 2	0.986	landscape →
P90986	—	0.986	P90986 →
Q8CGU9	—	0.986	Q8CGU9 →
Q2KIH7	—	0.985	Q2KIH7 →
B4P6P7	—	0.985	B4P6P7 →
F4IF36	—	0.985	F4IF36 →
Q9SLZ0	—	0.985	Q9SLZ0 →
A1ZAB5	—	0.985	A1ZAB5 →
Q64332	—	0.985	Q64332 →
B5X574	—	0.985	B5X574 →
Q9NPH2	—	0.985	Q9NPH2 →
B2B1M4	—	0.985	B2B1M4 →
Q9LXS6	—	0.985	Q9LXS6 →